Additional Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Newport Native MD, Inc.
    Newport Beach CA. 92663
    View Details

  • Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

    Southeastern Research Center
    Winston-Salem NC. 27103
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Saint Petersburg FL. 33704
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Vancouver V5Z 1M9
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Hamilton L8N 4A6
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Wilmington NC. 28401
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Newport Beach CA. 92663
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Philadelphia PA. 19140
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Trois RiviEres G8T 7A1
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    New York NY. 10065
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Ajax L1S 2J5
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Cypress CA. 77429
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Nashville TN. 37204
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Saint John's A1B 3V6
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Ann Arbor MI. 48109-5360
    View Details

  • A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    GSK Investigational Site
    Rochester NY. 55905
    View Details

  • Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

    University of Michigan
    Ann Arbor MI. 48109
    View Details

  • Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

    University of Virginia
    Charlottesville VA. 22908
    View Details

  • Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

    Massachusetts General Hospital
    Boston MA. 02114
    View Details

  • Move With Air: Physiological Response Assessment

    Centre of Innovative Medicine of the McGill University Health Centre
    Montreal QC. H4A 3J1
    View Details